Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of […]
Recent Content
- Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma
- Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
- Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma
- Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
- Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients
- Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
- Single Question Can Predict Treatment Discontinuation in MM Patients
- Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis
- Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
- Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria